BridgeBio Pharma, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Q3 2026 revenues totaled $353.2M ($253.2M Attruby net product sales, +$31M sequentially, +$145M YoY; plus $75M Bayer BEYONTTRA sales milestone). Cash position $1.5B as of Sept 30, 2026 (vs $587.5M Dec 31, 2025). Three late-stage pipeline programs approaching FDA decisions: BBP-418 (LGMD2I/R9, PDUFA Nov 27, 2026); oral infigratinib for achondroplasia (PDUFA Feb 4, 2027); encaleret for ADH1 (PDUFA May 8, 2027)—all Priority Review. Attruby continues outperforming tafamidis in real-world comparisons (18% lower risk of death/hospitalization/AFib/diuretic need vs tafamidis in 2,684-patient Epic COSMOS analysis, p<0.01).
Why this rating
Strong commercial execution (Attruby +145% YoY) materially above prior baseline. Three simultaneous FDA/EMA approvals in next 7 months could transform revenue profile. However, significance tempered: $1.5B cash covers burns; stock-based comp and debt service high; multi-year regulatory/commercialization risk remains.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.